+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Paroxysmal Nocturnal Hemoglobinuria Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768076
  • Report
  • April 2019
  • Region: Global
  • 69 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Amgen Inc
  • CMIC Holdings Co Ltd
  • Laboratory Corp of Am
  • MORE
The global clinical trial report- “2019 Paroxysmal Nocturnal Hemoglobinuria Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Paroxysmal Nocturnal Hemoglobinuria. It presents in-depth analysis of Paroxysmal Nocturnal Hemoglobinuria clinical trials across markets and companies. The research work is for providing complete understanding into trends in Paroxysmal Nocturnal Hemoglobinuria.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Paroxysmal Nocturnal Hemoglobinuria clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Paroxysmal Nocturnal Hemoglobinuria

The research work is prepared through extensive and continuous research on Paroxysmal Nocturnal Hemoglobinuria trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Paroxysmal Nocturnal Hemoglobinuria patients are identified
  • The report includes panorama of Paroxysmal Nocturnal Hemoglobinuria clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Paroxysmal Nocturnal Hemoglobinuria clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Amgen Inc
  • CMIC Holdings Co Ltd
  • Laboratory Corp of Am
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Paroxysmal Nocturnal Hemoglobinuria Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Region
2.2.2 Average Enrollment of Paroxysmal Nocturnal Hemoglobinuria Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Paroxysmal Nocturnal Hemoglobinuria Treatment, 2019

3. Region wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials
3.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Country
3.2 Europe Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Country
3.3 North America Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Country
3.4 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Country
3.5 South and Central America Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Country

4. Paroxysmal Nocturnal Hemoglobinuria Clinical Trial Trends
4.1 Start Year wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials
4.2 Phase wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials
4.3 Trial Status wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials
4.4 Trial Type wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials

5. Paroxysmal Nocturnal Hemoglobinuria Average Enrollment Trends
5.1 Average Enrollment in Paroxysmal Nocturnal Hemoglobinuria Trials by Year
5.2 Average Enrollment in Paroxysmal Nocturnal Hemoglobinuria Trials by Phase
5.3 Average Enrollment in Paroxysmal Nocturnal Hemoglobinuria Trials by Status
5.4 Average Enrollment in Paroxysmal Nocturnal Hemoglobinuria Trials by Type of Trial

6. Companies Participating in Paroxysmal Nocturnal Hemoglobinuria Clinical Trials
6.1 Paroxysmal Nocturnal Hemoglobinuria Trials by Sponsor Type
6.2 Paroxysmal Nocturnal Hemoglobinuria Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Paroxysmal Nocturnal Hemoglobinuria Trials- Phase 1
7.2 Paroxysmal Nocturnal Hemoglobinuria Trials- Phase 2
7.3 Paroxysmal Nocturnal Hemoglobinuria Trials- Phase 3
7.4 Paroxysmal Nocturnal Hemoglobinuria Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Figure 5: Europe - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Figure 7: North America - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Figure 9: Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Phase
Figure 10: Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Trial Status
Figure 11: Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Type
Figure 12: Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Sponsor Type
Figure 13: Paroxysmal Nocturnal Hemoglobinuria Clinical Trials by Leading Sponsors
Figure 14: Paroxysmal Nocturnal Hemoglobinuria Average Enrollment by Phase
Figure 15: Paroxysmal Nocturnal Hemoglobinuria Average Enrollment by Trial Status
Figure 16: Paroxysmal Nocturnal Hemoglobinuria Average Enrollment by Type
Figure 17: Paroxysmal Nocturnal Hemoglobinuria- Average Enrolment by Type of Sponsors
Figure 18: Paroxysmal Nocturnal Hemoglobinuria- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Paroxysmal Nocturnal Hemoglobinuria Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Table 5: Europe - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Table 7: North America - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Paroxysmal Nocturnal Hemoglobinuria Average Enrollment by Phase
Table 15: Paroxysmal Nocturnal Hemoglobinuria Average Enrollment by Trial Status
Table 16: Paroxysmal Nocturnal Hemoglobinuria Average Enrollment by Type
Table 17: Paroxysmal Nocturnal Hemoglobinuria- Average Enrolment by Type of Sponsors
Table 18: Paroxysmal Nocturnal Hemoglobinuria- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Achillion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • Apellis Pharmaceuticals Inc
  • Clinical Network Services (CNS) Pty Ltd
  • CMIC Holdings Co Ltd
  • Laboratory Corp of Am
Note: Product cover images may vary from those shown
Adroll
adroll